^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KRAS G13D + BRAF mutation

i
Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
over3years
Mucinous borderline ovarian tumors with BRAF mutation may have low risk for progression to invasive carcinomas. (PubMed, Arch Gynecol Obstet)
These results suggest that MBT with V600E BRAF mutation may rarely progress to MOC, while MBT with G12D or G13D KRAS mutation may more commonly progress to MOC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
TP53 mutation • BRAF V600E • KRAS mutation • BRAF mutation • PIK3CA mutation • BRAF V600 • KRAS G12D • KRAS G13D • KRAS G12 • KRAS G13 • KRAS G13D + BRAF mutation
over3years
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma. (PubMed, Proc Natl Acad Sci U S A)
Finally, a bortezomib (BTZ)/MEK inhibitor combination showed enhanced activity in vivo specifically in CA-NRAS models. Taken together, the data support the hypothesis that activating MAPK pathway mutations enhance PI resistance by increasing proteasome capacity, and provide a rationale for targeting such patients with PI/RAF or PI/MEK inhibitor combinations. Moreover, they argue these mutations promote myeloma survival by reducing cellular stress, thereby distancing plasma cells from the apoptotic threshold, potentially explaining their high frequency in myeloma.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
BRAF V600E • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G12V • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS Q61H • NRAS G13 • KRAS G13D + BRAF mutation
|
bortezomib
over3years
KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute. (PubMed, Blood Res)
We first showed the frequency of RAS/RAF mutations in Korean patients with PCM. Screening of these mutations could be considered as a routine clinical test at the time of diagnosis and follow-up due to their influence on clinical outcome, as well as its potential as a therapeutic target.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G12V • KRAS G13D • KRAS G12 • KRAS G13 • NRAS G12 • NRAS G13 • NRAS G13D • KRAS G13D + BRAF mutation • KRAS G61 • NRAS G12V
over3years
Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay. (PubMed, Nanotheranostics)
The blinded test using 9 samples from advanced CRC patients by PCR/SERS assay was validated with ddPCR and showed good consistency with pathology testing results. With ddPCR-like sensitivity yet at the convenience of standard PCR, the proposed assay shows great potential in sensitive detection of multiple ctDNA mutations for clinical decision-making.
Clinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • KRAS mutation • BRAF V600 • KRAS G12V • KRAS G13D • KRAS G12 • KRAS G13 • KRAS G13D + BRAF mutation